Inorganic Chemical
Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old
Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment
Mesoblast Secures FDA Approval for Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease
Mesoblast, Ryoncil, FDA Approval, Mesenchymal Stromal Cell Therapy, Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD), Pediatric Patients, Cell Therapy
Zelicapavir Shows Promising Antiviral Effect in Pediatric RSV Study
Zelicapavir, RSV, Antiviral, Pediatric, Phase 2 Study, Respiratory Syncytial Virus
Acadia Generates $100 Million from Pediatric Disease Priority Review Voucher Sale
Acadia Pharmaceuticals, Pediatric Disease Priority Review Voucher, Pharmaceutical Industry, Financial Transactions
Journey Medical’s Emrosi Receives FDA Approval, Setting New Standard for Rosacea Treatment
Rosacea treatment, Emrosi, FDA approval, Minocycline hydrochloride, Journey Medical Corporation, Dermatological conditions, New standard of care
Blue Earth Therapeutics Advances with $76.5M Series A Financing for Next-Gen Radiohybrid RLTs
Blue Earth Therapeutics, Series A financing, radiohybrid RLTs, Phase II studies, targeted therapies, lutetium, alpha emitter.
FDA Approves Avadel’s Lumryz for Pediatric Narcolepsy Patients
Avadel Pharmaceuticals, Lumryz, narcolepsy, pediatric patients, FDA approval, sodium oxybate, cataplexy, excessive daytime sleepiness (EDS)
Gritstone’s GRANITE Vaccine Shows Encouraging but Limited Benefit in Metastatic Colorectal Cancer
Gritstone bio, GRANITE, cancer vaccine, metastatic colorectal cancer, MSS-CRC, neoantigen targeting immunotherapy, progression-free survival, ctDNA
Gritstone Bio Explores Strategic Alternatives Amid Financial Strains and Mixed Cancer Vaccine Trial Results
Gritstone Bio, GRANITE, cancer vaccine, strategic alternatives, financial challenges, Phase 2 trial results
Novo Nordisk’s GLP-1 Agonist Demonstrates Significant BMI Reduction in Children Aged 6-12 in Phase 3 Trial
GLP-1 agonists, obesity, weight loss, liraglutide, semaglutide, pediatric obesity, BMI reduction, Novo Nordisk, Phase 3 trial.